Key clinical point: Abiraterone-enzalutamide sequence in patients with castration-resistant prostate cancer (CRPC) is associated with better progression-free survival (PFS), combined prostate-specific antigen (PSA)-PFS, and PSA response rates vs. enzalutamide-abiraterone sequence.

Major finding: Abiraterone-enzalutamide sequence vs. enzalutamide-abiraterone sequence was associated with significantly improved PFS (pooled hazard ratio [HR], 0.62; P less than .001), PSA-PFS (pooled HR, 0.48; P less than .001), and PSA response rates for first and second antiandrogens (risk ratio, 0.21; P less than .001).

Study details: Meta-analysis of 8 studies, including 643 patients with CRPC; the primary outcome was PFS.

Disclosures: No study sponsor was identified. The authors declared no conflict of interest.